Karen McAdam

Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial

Gary Middleton, Paul Silcocks, Trevor F. Cox et al. · The Lancet Oncology · 2014 · 370 citations · Full text

Pancreatic Cancer, Medicine, Immunology +5

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

Helena Earl, Louise Hiller, Anne-Laure Vallier et al. · The Lancet · 2019 · 277 citations · Full text

Epirubicin and Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy for Early Breast Cancer

Christopher Poole, Helena Earl, Louise Hiller et al. · New England Journal of Medicine · 2006 · 189 citations · Full text

Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial

Helena Earl, Louise Hiller, Janet Dunn et al. · The Lancet Oncology · 2015 · 133 citations · Full text

Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial

Helena Earl, Anne-Laure Vallier, Louise Hiller et al. · The Lancet Oncology · 2013 · 118 citations · Full text